Stocks and Investing Stocks and Investing
Thu, November 5, 2020

Jeffrey Hung Maintained (ACAD) at Buy with Increased Target to $58 on, Nov 5th, 2020


Published on 2024-10-27 14:38:56 - WOPRAI, Jeffrey Hung
  Print publication without navigation


Jeffrey Hung of Morgan Stanley, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $57 to $58 on, Nov 5th, 2020.

Jeffrey has made no other calls on ACAD in the last 4 months.



There are 7 other peers that have a rating on ACAD. Out of the 7 peers that are also analyzing ACAD, 1 agrees with Jeffrey's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $42 on, Tuesday, July 21st, 2020


These are the ratings of the 6 analyists that currently disagree with Jeffrey


  • Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $65 on, Tuesday, August 25th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $52 on, Thursday, August 6th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $60 on, Thursday, August 6th, 2020
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $61 on, Tuesday, July 21st, 2020
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $55 on, Tuesday, July 21st, 2020
  • Paul Matteis of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $71 on, Tuesday, July 7th, 2020
Contributing Sources